Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis

Antimicrob Agents Chemother. 2003 Apr;47(4):1419-22. doi: 10.1128/AAC.47.4.1419-1422.2003.

Abstract

Five Spain(9V-3) Streptococcus pneumoniae strains were isolated from a patient with bronchiectasis who had received long-term ciprofloxacin therapy. One ciprofloxacin-susceptible strain was isolated before treatment, and four ciprofloxacin-resistant strains were isolated during treatment. The resistant strains were derived from the susceptible strain either by a parC mutation (low-level resistance) or by parC and gyrA mutations (high-level resistance). This study shows that ciprofloxacin therapy in a patient colonized by susceptible S. pneumoniae may select fluoroquinolone-resistant mutants.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / therapeutic use*
  • Bronchiectasis / drug therapy*
  • Bronchiectasis / microbiology
  • Ciprofloxacin / therapeutic use*
  • Drug Resistance, Bacterial / genetics*
  • Humans
  • Male
  • Middle Aged
  • Mutation*
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / genetics*

Substances

  • Anti-Infective Agents
  • Ciprofloxacin